DKSH Announces Strategic Partnership with BridgeBio for Southeast Asia Expansion

DKSH Management Ltd. has announced a strategic distribution partnership with BridgeBio, a biotechnology company specializing in genetic diseases. This collaboration aims to support the regulatory evaluation and potential patient access to a transthyretin stabilizer for transthyretin-mediated amyloidosis (ATTR-CM) in selected Asia Pacific markets, including Australia, Singapore, South Korea, and Taiwan.

The transthyretin stabilizer is designed to treat cardiomyopathy linked to ATTR-CM and reduce cardiovascular deaths and hospitalizations in adults. However, its approval and distribution in the aforementioned regions are subject to local regulatory clearances.

DKSH's comprehensive commercialization platform will facilitate this partnership by ensuring effective distribution and market access. The endeavor marks a significant milestone towards improving healthcare solutions across underserved patient populations in Asia Pacific.